
Teva Pharmaceutical (TEVA) P/E Ratio
P/E Ratio as of Jun 30, 2025: -14.71
Average-15.11
Median-15.04
Minimum-15.86
Maximum-14.54
-14.71
Past Month+0.02 (0.14%)
The P/E ratio for Teva Pharmaceutical (TEVA) is -14.71 as of Jun 30, 2025. This represents a decrease of -46.27% compared to its 12-month average P/E ratio of -27.38. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Teva Pharmaceutical P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Teva Pharmaceutical’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Teva Pharmaceutical to industry peers.
Teva Pharmaceutical P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Teva Pharmaceutical’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Teva Pharmaceutical to industry peers.
Teva Pharmaceutical (TEVA) P/E Ratio Insights
See Teva Pharmaceutical’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares
Teva Pharmaceutical (TEVA) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $17.26 | -15.15 |
May 1, 2025 | $15.62 | -10.79 |
Apr 1, 2025 | $15.29 | -10.56 |
Mar 3, 2025 | $16.00 | -11.05 |
Feb 3, 2025 | $17.35 | -11.98 |
Jan 2, 2025 | $21.30 | -25.04 |
Teva Pharmaceutical (TEVA) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -14.71 | -43.23% |
2024 | -25.91 | +391.65% |
2023 | -5.27 | -32.69% |
2022 | -7.83 | -136.99% |
2021 | 21.17 | -898.87% |
2020 | -2.65 | — |
FAQs About Teva Pharmaceutical (TEVA) P/E ratio
The latest P/E ratio of Teva Pharmaceutical (TEVA) is -14.71, as of Jun 30, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Teva Pharmaceutical’s last 12-month average P/E ratio is -27.38, compared to its current P/E ratio of -14.71. This reflects a decrease of -46.27%.
Teva Pharmaceutical’s current P/E ratio of -14.71 is lower than its last 12-month average P/E of -27.38. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Teva Pharmaceutical’s average P/E ratio over the last 3 years is -17.29. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Teva Pharmaceutical’s average P/E ratio over the last 5 years is 127.65. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.